CYDY - CytoDyn reports leronlimab data in NASH trial for first 15 patients

CytoDyn (OTCQB:CYDY +2.5%) announces data from its trial treating NASH (nonalcoholic steatohepatitis) open label with leronlimab. Leronlimab open label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for NAFLD (Non-Alcoholic Fatty Liver Deposit) but also in NASH. Fat reductions by proton density fat fraction PDFF up to 45% along with reductions in fibrosis up to 8% by CT1 were noted from baseline after just 14 weeks of treatment. The reductions in fibrosis were seen in both severe and mild-moderate NASH cases. “CytoDyn will now file for Fast Track Designation for both the indications of NASH and NAFLD. Once the full results are reported, which we anticipate to be available in mid-December, we may proceed to file a Phase 3 protocol with the FDA and request accelerated approval,” stated Nader Pourhassan, Ph.D., CytoDyn’s President and CEO. Recently, CytoDyn (OTCQB:CYDY) submitted the first

For further details see:

CytoDyn reports leronlimab data in NASH trial for first 15 patients